Are probiotics effective for preventing chemotherapy-induced diarrhea? Conditional benefits and remaining evidence gaps

PURPOSE OF REVIEW: Chemotherapy-induced diarrhea (CID) is a clinically significant toxicity that may impair nutritional status, quality of life, treatment continuity, and dose intensity. As CID is increasingly linked to gut dysbiosis, epithelial barrier dysfunction, inflammatory activation, and altered microbiota-host interactions, probiotics have been proposed as a potential preventive strategy. This review evaluates recent clinical and translational evidence on whether probiotics can prevent CID and in which settings benefit appears most plausible. RECENT FINDINGS: Evidence published over the past 18 months has refined rather than fundamentally changed previous conclusions. Most recent data come from systematic reviews and meta-analyses, whereas newly published randomized or prospective clinical studies remain limited. Pooled analyses suggest that probiotic supplementation is associated with a lower risk of diarrhea, particularly in fluoropyrimidine- or irinotecan-based chemotherapy and in gastrointestinal malignancies, including colorectal cancer. Similar signals have also been reported in selected leukemia chemotherapy populations. However, these estimates remain limited by heterogeneity in treatment setting, probiotic formulation, dose, timing, duration, and outcome definition, and many still depend on earlier trials. Translational studies further support a strain-specific and context-dependent model involving microbial metabolites, epithelial barrier protection, inflammatory regulation, and drug-microbiota interactions. SUMMARY: Current evidence does not support routine probiotic prophylaxis for all patients receiving chemotherapy. A more appropriate interpretation is that probiotics may represent candidate adjunctive preventive strategies in selected high-risk CID settings, particularly when the chemotherapy regimen, patient risk profile, probiotic intervention, and clinical endpoints are clearly defined. Future studies should move from broad probiotic supplementation toward regimen-specific, strain-defined, and risk-stratified trials, with standardized CID outcomes, rigorous safety monitoring, and assessment of treatment continuity, dose intensity, and antitumor efficacy.